Scholarlink

<p>Osteoporosis (OP) is a chronic systemic metabolic bone disorder that requires further exploration of effective treatments. An optimal anti-osteoporosis agent should exert dual effects on both osteoblasts and osteoclasts. Hydroxysafflor yellow A (HSYA), a flavonoid from the traditional Chinese medicinal plant safflower, is recognized as a potential candidate. This study shows that HSYA supports bone formation by stimulating osteoblast differentiation and increasing calcium nodule deposition. HSYA activates the PI3K/AKT signaling pathway and upregulates Runx2 expression in an in vitro osteoblast differentiation model using BMSCs. Concurrently, HSYA inhibit osteoclast differentiation, thereby mitigating the excessive bone resorption associated with osteoporosis. These findings indicate that HSYA mitigates bone loss in OP in vivo, while enhancing osteoblast activity and activating the PI3K/AKT pathway in an in vitro osteoblast differentiation model using BMSCs, and inhibiting osteoclast-driven bone resorption.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hydroxysafflor yellow A attenuatesovariectomy induced bone loss andpromotes osteogenesis via PI3K/AKT activation in an in vitro BMSC model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Mingzhou Wu,
  • Wei Wang,
  • Zhongwei Ji,
  • Kai Zheng,
  • Weicheng Zhang,
  • Gaoran Ge,
  • Chunyang Fan,
  • Dechun Geng,
  • Yaozeng Xu,
  • Jun Zhou

摘要

Osteoporosis (OP) is a chronic systemic metabolic bone disorder that requires further exploration of effective treatments. An optimal anti-osteoporosis agent should exert dual effects on both osteoblasts and osteoclasts. Hydroxysafflor yellow A (HSYA), a flavonoid from the traditional Chinese medicinal plant safflower, is recognized as a potential candidate. This study shows that HSYA supports bone formation by stimulating osteoblast differentiation and increasing calcium nodule deposition. HSYA activates the PI3K/AKT signaling pathway and upregulates Runx2 expression in an in vitro osteoblast differentiation model using BMSCs. Concurrently, HSYA inhibit osteoclast differentiation, thereby mitigating the excessive bone resorption associated with osteoporosis. These findings indicate that HSYA mitigates bone loss in OP in vivo, while enhancing osteoblast activity and activating the PI3K/AKT pathway in an in vitro osteoblast differentiation model using BMSCs, and inhibiting osteoclast-driven bone resorption.